AIZ vs GL

Assurant (AIZ) shows mixed financial health with a weak Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score, limiting distress risk assessment. The stock trades above its Graham Number of $204.04 at $233.39, suggesting a modest premium, but below the analyst target of $259.33. Strong earnings growth (YoY +102.7%) and consistent earnings beat rates (3 of last 4 quarters) support valuation, yet weak technicals (10/100) and negative insider activity raise caution. Profitability metrics like ROE (15.41%) and low debt/equity (0.38) are positives, but liquidity concerns are evident in a weak current ratio (0.41) and quick ratio (0.15).

Globe Life Inc. presents a stark contrast between attractive valuation and deteriorating fundamental health. While the stock trades below its Graham Number ($159.37) and maintains a strong ROE of 20.46%, the Piotroski F-Score of 2/9 indicates significant weakness in financial quality and operational efficiency. This fundamental decay is compounded by bearish insider sentiment, including sales by the CEO and CIO, and a low current ratio of 0.66 suggesting liquidity constraints. Despite analyst 'buy' recommendations, the deterministic health markers suggest a high-risk profile that offsets the low P/E multiple.